Therapy Focus: Immunotherapy Crowds Bladder Cancer Space – Seeking Alpha
|
Therapy Focus: Immunotherapy Crowds Bladder Cancer Space
Seeking Alpha Roche's (OTCQX:RHHBY, OTCQX:RHHBF) Tecentriq is the one to beat after cementing a win in first line last month – the first immunotherapy to do so. Bristol-Myers Squibb's (NYSE:BMY) Opdivo is approved for second line, while Merck's (NYSE:MRK) … |
